Subgroup analysis indicated that treatment efficacy remained consistent regardless of the specific sGC type but may vary across different forms of chronic kidney disease.<h4>Conclusion</h4>This preclinical meta-analysis indicates that sGC stimulators and activators exert renoprotective effects in CKD, with efficacy potentially influenced by disease etiology. Here, SGCB is linked to chronic kidney disease.